TY - JOUR
T1 - Endothelial Function in Human Immunodeficiency Virus-Infected Antiretroviral-Naive Subjects Before and After Starting Potent Antiretroviral Therapy. The ACTG (AIDS Clinical Trials Group) Study 5152s
AU - Torriani, Francesca J.
AU - Komarow, Lauren
AU - Parker, Robert A.
AU - Cotter, Bruno R.
AU - Currier, Judith S.
AU - Dubé, Michael P.
AU - Fichtenbaum, Carl J.
AU - Gerschenson, Mariana
AU - Mitchell, Carol K.C.
AU - Murphy, Robert L.
AU - Squires, Kathleen
AU - Stein, James H.
N1 - Funding Information:
This multicenter trial was conducted by the AIDS Clinical Trials Group (ACTG) funded by the National Institute of Allergy and Infectious Diseases and the National Heart, Lung, and Blood Institute. Pharmaceutical support was provided by Abbott Laboratories and Bristol-Myers Squibb Company. The following additional grants were received: NIH AI069424, AI56933, and AI069428 (to Dr. Currier); NIH AI25859, HL72711, RR00750, and RR000750 (to Dr. Dubé); NIH AI069513 (to Dr. Fichtenbaum); NIH AI34853, RR16467, and MD000173 (to Dr. Gerschenson); NIH AI069471 (to Dr. Murphy); NIH AI38855 and AI068634 (to Ms. Komarow); NIH AI38855 and AI068634 (to Dr. Parker); NIH RR16176 and AI25915 (to Dr. Stein); NIH AI69432 (to Dr. Torriani); and NIH AI38558 and NIH AI068636 (to the ACTG leadership). Dr. Torriani is on the advisory board for Abbott. Dr. Currier has received research grants from Merck and Co., Tibotec, GlaxoSmithKline, Theratechnologies, and Schering-Plough; has received honoraria from Gilead, Koronnis, Achillion, and Vertex; and has been a consultant/advisory board member for Bristol-Myers Squibb, Pfizer, Merck, and Gilead. Dr. Dubé has received research grants from Abbott and Bristol-Myers Squibb and has been a consultant to GlaxoSmithKline, Tibotec, Gilead, Bristol-Myers Squibb, and Abbott. Dr. Fichtenbaum has received research grants from Abbott and Bristol-Myers Squibb; has been on the Speakers' Bureaus of Abbott, Bristol-Myers Squibb, and Gilead; and has received honoraria from Abbott, Bristol-Myers Squibb, and Gilead. Dr. Murphy has received research grants from Bristol-Myers Squibb and has been a consultant/advisory board member for Gilead and Bristol-Myers Squibb. Dr. Squires has received a research grant from Bristol-Myers Squibb; has received honoraria from Gilead Sciences, Bristol-Myers Squibb, and Abbott; and has been on the advisory board for Bristol-Myers Squibb, Gilead Sciences, and Abbott. Dr. Stein has received a research grant from Bristol-Myers Squibb and has been a consultant for Abbott. Joseph A. Vita, MD, served as Guest Editor for this article.
PY - 2008/8/12
Y1 - 2008/8/12
N2 - Objectives: This study evaluated the effects of 3 class-sparing antiretroviral therapy (ART) regimens on endothelial function in human immunodeficiency virus (HIV)-infected subjects participating in a randomized trial. Background: Endothelial dysfunction has been observed in patients receiving ART for HIV infection. Methods: This was a prospective, multicenter study of treatment-naive subjects who were randomly assigned to receive a protease inhibitor-sparing regimen of nucleoside reverse transcriptase inhibitors (NRTIs) + efavirenz, a non-nucleoside reverse transcriptase inhibitor-sparing regimen of NRTIs + lopinavir/ritonavir, or a NRTI-sparing regimen of efavirenz + lopinavir/ritonavir. The NRTIs were lamivudine + stavudine, zidovudine, or tenofovir. Brachial artery flow-mediated dilation (FMD) was determined by B-mode ultrasound before starting on ART, then after 4 and 24 weeks. Results: There were 82 subjects (median age 35 years, 91% men, 54% white). Baseline CD4 cell counts and plasma HIV ribonucleic acid (RNA) values were 245 cells/mm3 and 4.8 log10 copies/ml, respectively. At baseline, FMD was 3.68% (interquartile range [IQR] 1.98% to 5.51%). After 4 and 24 weeks of ART, plasma HIV RNA decreased by 2.1 and 3.0 log10 copies/ml, respectively. FMD increased by 0.74% (IQR -0.62% to +2.74%, p = 0.003) and 1.48% (IQR -0.20% to +4.30%, p < 0.001), respectively, with similar changes in each arm (Kruskal-Wallis p value >0.600). The decrease in plasma HIV RNA at 24 weeks was associated with greater FMD (rs = -0.30, p = 0.017). Conclusions: Among treatment-naive individuals with HIV, 3 different ART regimens rapidly improved endothelial function. Benefits were similar for all ART regimens, appeared quickly, and persisted at 24 weeks.
AB - Objectives: This study evaluated the effects of 3 class-sparing antiretroviral therapy (ART) regimens on endothelial function in human immunodeficiency virus (HIV)-infected subjects participating in a randomized trial. Background: Endothelial dysfunction has been observed in patients receiving ART for HIV infection. Methods: This was a prospective, multicenter study of treatment-naive subjects who were randomly assigned to receive a protease inhibitor-sparing regimen of nucleoside reverse transcriptase inhibitors (NRTIs) + efavirenz, a non-nucleoside reverse transcriptase inhibitor-sparing regimen of NRTIs + lopinavir/ritonavir, or a NRTI-sparing regimen of efavirenz + lopinavir/ritonavir. The NRTIs were lamivudine + stavudine, zidovudine, or tenofovir. Brachial artery flow-mediated dilation (FMD) was determined by B-mode ultrasound before starting on ART, then after 4 and 24 weeks. Results: There were 82 subjects (median age 35 years, 91% men, 54% white). Baseline CD4 cell counts and plasma HIV ribonucleic acid (RNA) values were 245 cells/mm3 and 4.8 log10 copies/ml, respectively. At baseline, FMD was 3.68% (interquartile range [IQR] 1.98% to 5.51%). After 4 and 24 weeks of ART, plasma HIV RNA decreased by 2.1 and 3.0 log10 copies/ml, respectively. FMD increased by 0.74% (IQR -0.62% to +2.74%, p = 0.003) and 1.48% (IQR -0.20% to +4.30%, p < 0.001), respectively, with similar changes in each arm (Kruskal-Wallis p value >0.600). The decrease in plasma HIV RNA at 24 weeks was associated with greater FMD (rs = -0.30, p = 0.017). Conclusions: Among treatment-naive individuals with HIV, 3 different ART regimens rapidly improved endothelial function. Benefits were similar for all ART regimens, appeared quickly, and persisted at 24 weeks.
KW - antiretroviral therapy
KW - cardiovascular disease risk
KW - endothelial function
KW - human immunodeficiency virus
UR - http://www.scopus.com/inward/record.url?scp=48449086593&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=48449086593&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2008.04.049
DO - 10.1016/j.jacc.2008.04.049
M3 - Article
C2 - 18687253
AN - SCOPUS:48449086593
SN - 0735-1097
VL - 52
SP - 569
EP - 576
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 7
ER -
